報價延遲最少15分鐘:2025/03/20 05:39 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.02 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.28/-0.72
|
|
企業價值
95.72M
|
| 資產負債 |
|
每股賬面淨值
1.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
24.35M
|
|
每股收益
0.47
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/20 05:39 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States. |